# WVE-006

Type: Product

Source: GetYourBrief — https://getyourbrief.com/entity/wve-006
Canonical HTML page: https://getyourbrief.com/entity/wve-006

## Recent coverage (3 stories, network-wide)

### Wave's WVE-007 Silences Activin E by 88%, Sustained for 7.5 Months in Phase I
2026-08-04 04:01:27 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wave Life Sciences presented Phase I data for WVE-007, an siRNA targeting Activin E, demonstrating up to 88% serum reduction sustained for over 7.5 months. The INLIGHT Phase IIa trial is now enrolling 160 patients across four cohorts, with a focus on BMI 35–50 and type 2 diabetes status, aiming to validate the RNA editing platform's potential for durable obesity treatment.
Full story: https://getbiobrief.com/story/wave-007-88-percent-activin-e-silencing

### Wave's Obesity siRNA Shows 16.5% Visceral Fat Improvement, Targeting 175M Patients
2026-08-04 03:59:45 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wave Life Sciences' WVE-007, a novel siRNA silencing Activin E, demonstrated a 16.5% improvement in visceral fat-to-muscle ratio in Phase I, outpacing existing therapies and offering a potential solution for the 70% of GLP-1 users who discontinue within a year. With enrollment underway in the INLIGHT Phase IIa trial, the 175 million individuals with obesity in the U.S. and Europe may soon have a longer-lasting, disease-modifying option.
Full story: https://gethealthbrief.com/story/wave-obesity-siRNA-16-5-vmr

### Wave Life Sciences and Collegium FY2025 Results Signal RNA and Pain Pivot
2026-02-26 14:28:36 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wave Life Sciences and Collegium Pharmaceutical reported full-year 2025 results, highlighting a transformative period for RNA editing and commercial pain management. Wave's clinical progress in AATD and DMD remains a primary valuation driver, while Collegium continues to optimize its specialized portfolio through strategic acquisitions.
Full story: https://getbiobrief.com/story/wave-life-sciences-collegium-fy2025-earnings-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.